Allianz Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Allianz Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,045	Closed	-$1.32M	–	2360
2020 Q4	$1.32M	Sell	10,045 -10,688	-52%	-$944K	﹤0.01%	1421
2020 Q3	$1.05M	Sell	20,733 -556	-3%	-$25K	﹤0.01%	1423
2020 Q2	$1.01M	Sell	21,289 -1,512	-7%	-$70.3K	﹤0.01%	1822
2020 Q1	$1.12M	Buy	22,801 +4,160	+22%	+$212K	﹤0.01%	1752
2019 Q4	$1.07M	Buy	+18,641	New	+$923K	﹤0.01%	2162
2019 Q3	–	Sell	-42,096	Closed	-$1.31M	–	2846
2019 Q2	$1.31M	Sell	42,096 -3,525	-8%	-$95.6K	﹤0.01%	2048
2019 Q1	$1.07M	Buy	+45,621	New	+$732K	﹤0.01%	2066

Allianz Asset Management's EIDX Position: Q1 2021 in Review

Allianz Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 10,045 shares — an estimated $1.32M sold.

Allianz Asset Management first reported a position in EIDX in Q1 2019 and held it in 7 quarters. The position peaked at $1.32M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Allianz Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Allianz Asset Management sold 10,045 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.32M.
Allianz Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
Allianz Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $1.32M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Allianz Asset Management's 13F filing for Q1 2021, filed 13 May 2021.